1.. Introduction
================

Current methodologies to determine the species that define or identify one particular clinical condition present several drawbacks, even when leading to reliable results. Requirements of previous separative steps, the need to count with highly trained personnel to perform the analysis, its frequent high cost, the circumscription to state-of-the-art laboratories are, among others, the main reasons that have prompt the search for new analytical technology to achieve advantageous clinical diagnostic methods \[[@b1-sensors-08-01366]\]. Biosensors emerge as upbeat technology to face this challenge.

Biosensors have been defined as compact analytical devices that bring together the use of a biological, a biologically-derived or a biomimic element to recognize the analyte. They are closely associated with, or integrated to, a signal conversion unit, the so-called physicochemical transducer, which eventually leads to a read-out. The use of biological materials as recognizing elements gives biosensors a remarkable ability to specifically react with the analyte of interest, distinguishing it from structurally similar compounds.

Taking into account the biomolecule that recognizes the target analyte, biosensors can be named as (*i*) affinity sensors, when the bioreceptor uses non-covalent interactions like antibody-antigen reactions or DNA strand hybridisation, and (*ii*) catalytic or enzyme sensors, when the analyte is the enzyme substrate, or it can be detected by measuring the signal produced by one substrate or product of the enzymatic reaction involving the analyte. Biosensors are also classified according to the parameter that is measured by the physicochemical transducer of the biological event. Thus, classically biosensors are grouped into optical, electrochemical, acoustic and thermal ones. Considering that electrochemical reactions directly generate an electronic signal, biosensors based on this approach greatly simplifies signal transduction, avoiding expensive equipment requirement.

Among electrochemical biosensors, the oldest ones, which have led to the higher number of ready-to-use devices, are based on the monitoring of electron-transfer processes, thus belonging to the amperometric category. This review will centre on this group. The signal of these biosensors is generated by the electron exchange between the biological system in the bioreceptor layer and one electrode. Generally speaking, when using amperometric biosensors, the analyte undergoes, or is involved, in a redox reaction that can be followed by measuring the current in an electrochemical cell. The analyte, or the species involved with it via a (bio)chemical reaction, changes its oxidation state at one electrode. The electron flux is then monitored and is proportional to the amount of the species electrochemically transformed at the electrode. [Figure 1](#f1-sensors-08-01366){ref-type="fig"} depicts the working principles of an amperometric biosensor.

The typical electrochemical technique performed when working with electron-transfer-based biosensors is chronoamperometry, in which the current is measured as a function of time, when the electrode is driven at an appropriate constant potential. [Figure 2A](#f2-sensors-08-01366){ref-type="fig"} shows a standard curve obtained when using an amperometric bioelectrode, in which the current varies upon the addition of a particular compound (*e.g.* a redox-enzyme substrate) to render a particular product that is electro-transformed at the electrode. The current change registered is proportional to the amount of electro-oxidized/reduced species, which in turn may be directly or inversely proportional to the analyte concentration, depending on the assay format.

Other electrochemical techniques, based on the electrochemical oxidation/reduction of species directly or indirectly involved in the recognizing biological reaction have been used when dealing with electron-transfer based biosensors. For example, it is possible to follow the amount of a species that is electro-transformed at one electrode by monitoring the time taken to perform such a reaction, when working at constant current, and varying the electrode potential. [Fig. 2B](#f2-sensors-08-01366){ref-type="fig"} depicts a typical curve obtained when carrying out one of these experiments, named potentiometric stripping analysis. The peak area is proportional to the time necessary to electro-transform a species attached to the electrode, which, for example, may be directly proportional to the analyte concentration.

Several other electrochemical techniques are also employed when using electron-transfer-based biosensors, such as stripping voltamperometry, differential pulse voltamperometry, coulometry, etc. These methodologies essentially measure parameters related to the amount of electro-transformed material on the electrode as current flows in the cell.

Clark and Lyons presented the precursor of today\'s biosensors in the early sixties \[[@b2-sensors-08-01366]\], though it was named "the enzyme electrode" rather than a glucose amperometric bioelectrode ([Figure 3](#f3-sensors-08-01366){ref-type="fig"}). The analyte, glucose, diffuses through a dialysis membrane to reach the trapped enzyme, glucose oxidase, which is placed very close to the surface of a platinum electrode. In the presence of the enzyme and oxygen, the analyte produces glucuronic acid and hydrogen peroxide. Monitoring the decrease in oxygen concentration allows to determine the glucose concentration of the medium bathing the outside face of the dialysis membrane. In this case, oxygen is reduced at the metal electrode polarized with a constant potential, and the current flowing in the cell is proportional to the oxygen concentration in the solution. Soon after Clark\'s proposal, Updike *et al.* introduced modifications to this first approach to avoid oxygen concentration dependence. They monitored the current flowing in the cell when one of the products of the enzymatic reaction, hydrogen peroxide, was oxidized on an electrode at a convenient potential \[[@b3-sensors-08-01366]\].

Today, Clark\'s brilliant, pioneering development has evolved, reaching the markets as "blood-glucose, self-testing biosensors". It is routinely used for screening and treating diabetes -an illness whose prevalence is *ca*. 4% of the population in industrialized countries- the equipment being worldwide sold by leader sensor companies \[[@b4-sensors-08-01366]\].

2.. Selectivity-Specificity
===========================

2.1.. Choosing the bioreceptor system
-------------------------------------

The bioreceptor layer is responsible for the selectivity/specificity of the device and, in principle, any biological or biologically derived element can be used. [Figure 4](#f4-sensors-08-01366){ref-type="fig"} summarizes the different bioreceptors we can use to achieve the desired selectivity, according to the nature of the analyte.

It should be noticed that this is the foremost feature of biosensors, since provides the devices the capacity of working without previous treatments of the sample, thus conferring speed to the analysis. The first task when designing a biosensor is to select a suitable bioreceptor system so that the recognition sites interact specifically with the target analyte. This choice depends on the analyte properties and structure, and on the presence of similar interfering substances potentially present in the sample. In clinical-chemical analysis, we deal with biological samples, which display a complex matrix likely carrying interferences.

### 2.1.1.. Enzymes

The extraordinary specificity displayed by enzymes for their natural substrates makes them the first candidates to be incorporated as the biorecognition element. In principle, we can use redox enzymes that react with the analyte producing products that can be monitored by amperometry via their oxidation/reduction on an electrode, as it was illustrated above with Clark\'s glucose biosensor. It is worth mentioning here that, when designing enzyme-based biosensors, an important issue is regaining the original oxidation state of the redox active site, so as to keep the enzyme active to react further with its substrate. Generally speaking, it is not feasible to oxidise/reduce the active site of one enzyme by setting directly the electrode potential at any particular value (an exception will be discussed later regarding oriented attachment of bioactive materials in point *3.1*). Most of the enzymes used in biosensor technology have their redox centre inside a pocket or at the core of the protein, so that the active site is electrically insulated. This difficulty is commonly tackled by using redox charge mediators, which transport the charge between the enzyme active site and the electrode surface. This subject will be discussed later in section *2.2*.

Though it would be desirable to electrochemically detect changes in the enzyme substrate (the analyte) or in one reaction product, most of the analytes of clinical interest are not natural substrates of a redox enzyme. A variety of strategies have been developed to work this problem out, depending on the analyte chemical properties. They are based upon the fact that it is feasible to transform a non-redox reaction into a redox one, which involves an enzyme that changes the oxidation number of the species that can be monitored by amperometry. These enzymes are sometimes used as label or reporter of the biological recognition event. Consequently, it has been proposed the use of coupled enzymatic reactions following the one where the analyte participates, to finally produce a species detectable by amperometry. The design below has been proposed by Tsuchida *et al.* to detect creatine, an important product of protein catabolism, and creatinine, one indicator of kidney function \[[@b5-sensors-08-01366]\]. The coupled reactions are shown in [equations 1](#FD1){ref-type="disp-formula"} to [3](#FD3){ref-type="disp-formula"}. They ultimately produce hydrogen peroxide, the species that is electrochemically transformed at the electrode to generate an amperometric signal.
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Other biosensors to determine analytes of clinic relevance have been developed, using redox enzymes that allow for the detection of the oxidation or reduction of one product directly or indirectly involved in the enzymatic reaction. They include amperometric biosensors to determine urea \[[@b6-sensors-08-01366]\], lactate \[[@b7-sensors-08-01366]-[@b9-sensors-08-01366]\] and pyruvate \[[@b10-sensors-08-01366]\], among others.

### 2.1.2.. Antibodies, antigens & aptamers

When a foreign compound, called antigen (Agn), enters one individual\'s body, its immunological system generally produces proteins, antibodies (Abs), which bind to such Agn with remarkable specificity. Nowadays, Abs can be either produced by inoculation of the Agn to an immuno-competent individual, or by genetic engineering of bacterial or animal cells \[[@b11-sensors-08-01366]\]. Moreover, currently, it is possible to produce Abs against almost any molecule (analyte), even those unable to stimulate naturally the immune system \[[@b12-sensors-08-01366]\].

Biosensor technology has taken advantage of the high specificity of the Agn-Ab reaction and, since decades, a myriad of research work aimed to clinical-chemistry analysis was carried out \[[@b13-sensors-08-01366]\]. Thus, when the clinical analyte of interest is an Agn, or it can be chemically modified to behave as an Agn, it is possible to use the complementary Abs as capturing molecules in the bioreceptor system. Abs usually interact exclusively with their complementary Agns, thus conferring a remarkable specificity to the device. In this case, the biosensor will be called immunosensor, named after the usage of Abs as bioreceptors.

The use of one enzyme-labelled antigen, added together with the sample carrying the analyte, allows to perform a competitive assay, in a similar way to competitive, enzyme linked immunosorbent assays (ELISA). [Figure 5A](#f5-sensors-08-01366){ref-type="fig"} depicts the competitive immunosensor format, where the target analyte competes with the labelled antigen for the biorecognition sites of the antibody attached to the electrode. After rinsing the system, the addition of the redox-enzyme-label substrate generates the product, which is transformed at the electrode, or reacts with one electroactive enzyme co-substrate further added, leading to a detectable current. In this competitive assay, the signal diminishes as the analyte concentration increases.

Diagnostic electron-transfer-based immunosensors have been reported to detect cancer markers, such as prostate specific antigen \[[@b14-sensors-08-01366],[@b15-sensors-08-01366]\] and carcinoembryonic antigen \[[@b16-sensors-08-01366]\], a pregnancy-indicator hormone, human chorionic gonadotrophine (hCG) \[[@b17-sensors-08-01366]\], the hormone indicative of ovary function, progesterone \[[@b18-sensors-08-01366]\], cholesterol \[[@b19-sensors-08-01366]\], creatinine \[[@b20-sensors-08-01366]\], and auto-antibodies of Type I diabetes \[[@b21-sensors-08-01366]\], among others. The reader is referred to wide-ranging immunosensor reviews such as those listed in references \[[@b13-sensors-08-01366],[@b22-sensors-08-01366],[@b23-sensors-08-01366]\].

When the analyte is an Ab, which is usually the case when diagnosing an infection, another immunological assay scheme can be performed, similar to that used to detect Agns. In this case, the bioreceptor is the Agn, which captures the specific Ab from the sample. A subsequently added redox, enzyme-labelled secondary Ab towards a particular region of the analyte (*e.g.* the Fc region of human immunoglobulin G, IgG, see below) will be captured on the surface of the modified electrode. The occurrence of a current once the substrate of the enzyme label is added evidences the presence of the analyte in the sample. In this case, one expects the signal to increase with the analyte concentration. [Figure 5B](#f5-sensors-08-01366){ref-type="fig"} illustrates the working principle of an indirect immunoassay format with amperometric detection. Biosensors using this format have been proposed by our group \[[@b24-sensors-08-01366]\], and by Ferreira *et al* \[[@b25-sensors-08-01366]\], to detect Chagas\' disease, the most serious parasitosis in South America. Other clinically relevant infections, such as those caused by *Schistosoma japonicum* \[[@b26-sensors-08-01366],[@b27-sensors-08-01366]\] and hantavirus \[[@b28-sensors-08-01366]\], have been detected with this strategy.

Despite the outstanding specificity of the Agn-Ab reaction, sometimes, cross-reactions may occur. False-positive results are generally associated with the occurrence of non-specific Abs, which are often developed by individuals suffering from other diseases. For instance, when a patient is infected with a microorganism phylogenetically related with the one whose infection is to be determined, this individual may have produced Abs against orthologous proteins of both infective agents. Therefore, the use of natural proteins of the microorganism as capturing Agn may lead to incorrect results. In these cases, synthetic recombinant proteins can assist to work the problem out. Recombinant proteins are generally synthesized from DNA sequences engineered to encode peptide fragments where the specific regions responsible of cross-reactivity have been excised \[[@b29-sensors-08-01366],[@b30-sensors-08-01366]\]. The use of recombinant DNA machinery to obtain specific, tailor-made proteins, together with biosensor technology, emerges as an auspicious means to achieve ready-to-use devices. They allow not only to obtain the analyte-exclusive bioreceptor, but also to simplify their attachment to the electrode surface (see below, item *3.2.*). Our group has synthesized such proteins for chagasic infection diagnosis. Results obtained with amperometric biosensors assembled with the new synthetic proteins have been presented in a preliminary work \[[@b31-sensors-08-01366]\]. The recombinant proteins produced allowed not only to obtain a unique analyte-capturing bioreceptor, but also to attach it to the electrode in an oriented manner.

Recently, aptamers have also been used as analyte-capturing species. Aptamers are linear nucleotide sequences, usually of 15- to 40-nucleotide length, undergoing many intramolecular interactions, which wrinkle the oligonucleotide chain. Therefore, aptamers present a three-dimensional shape that confers the molecules the aptitude to interact either strongly or weakly with partner molecules, depending on their structure. The enormous diversity of aptamer conformational structure, which varies with the nucleotide sequence, allows them to be selected according to the strength of interaction with their partner molecule \[[@b32-sensors-08-01366],[@b33-sensors-08-01366]\]. Thus, aptamers can be chosen so as to tightly and selectively bind to target molecules, including among them virtually any kind of analyte, *e.g.* proteins, lipids, carbohydrates, DNA, etc. \[[@b33-sensors-08-01366],[@b34-sensors-08-01366]\]. Moreover, aptamers are easily synthesised and isolated. They are more stable than, for example, antibodies, allowing to build up robust biosensors that, at variable settings, do not lose their remarkable specificity \[[@b35-sensors-08-01366],[@b36-sensors-08-01366]\]. These are the reasons why, in the lately years, scientists have preferred the use of aptamers as recognizing element when developing biosensors \[[@b33-sensors-08-01366],[@b37-sensors-08-01366]-[@b43-sensors-08-01366]\]. Numerous clinically related aptamer-based biosensors have been designed, as for example, one to detect 17β-estradiol, a hormone indicative of ovary function \[[@b44-sensors-08-01366]\]. Likewise, electron-transferred based aptasensors to determine small molecules like cocaine in biological fluids have been also developed \[[@b45-sensors-08-01366]\], as well as others to determine thrombin \[[@b46-sensors-08-01366]-[@b48-sensors-08-01366]\]; thrombin is the main executioner of the coagulation cascade, and its determination in blood is useful to assess the haemostatic status of patients for the diagnosis of coagulation and thrombotic disorders \[[@b49-sensors-08-01366]\]. Another related aptasensor is the one used to determine simultaneously lysozyme and thrombin \[[@b50-sensors-08-01366]\]; serum lysozyme has been proposed to be a marker of chronic inflammatory diseases, such as sarcoidosis, tuberculosis and liver and bowel inflammatory diseases, as well as of leukemia \[[@b51-sensors-08-01366]\]. Extensive and detailed aptamer-based sensor technology is reviewed in references \[[@b33-sensors-08-01366],[@b34-sensors-08-01366],[@b42-sensors-08-01366],[@b52-sensors-08-01366]\].

### 2.1.3.. Nucleic acids

Clinical-chemistry analysis often involves the detection of specific nucleotide sequences related to either a particular microorganism, which may be the causal agent of an infection, or DNA mutations that originate genetic diseases, or that are connected with high probability to develop certain type of diseases. Nucleic acid hybridisation is a thermodynamically favoured process, triggered by highly specific base-pairing interactions, where each nucleotide base strongly binds to its complementary base through several hydrogen bonds, efficiently sticking the bases together. Accordingly, DNA/RNA strands are excellent applicants to be used as recognizing elements to build up bioreceptor layers.

In the minimal configuration of amperometric DNA- or RNA-based biosensors, a single-stranded (ss-), nucleic acid sequence is anchored to an electrode to capture the analyte, in this case, its complementary DNA or RNA strand. Once the binding partners have met, the event is detected using different approaches, mostly by using an electrochemical reporter of the hybridisation \[[@b53-sensors-08-01366]-[@b56-sensors-08-01366]\]. Since the early sixties, Palecek and co-workers have been studying nucleic acids electrochemically \[[@b57-sensors-08-01366]-[@b59-sensors-08-01366]\], and have proposed a number of strategies to detect hybridisation \[[@b60-sensors-08-01366]-[@b62-sensors-08-01366]\]. A vast literature has been published on DNA hybridisation detection, some of them included in references \[[@b63-sensors-08-01366]-[@b68-sensors-08-01366]\]. Clinical applications using DNA-amperometric-based biosensors include devices potentially useful to determine indicators of pathogenic bacteria \[[@b69-sensors-08-01366]\], virus DNA sequence such as that of SARS virus \[[@b70-sensors-08-01366]\], indicators of chronic myelogenous leukemia \[[@b71-sensors-08-01366]\], and acute promyelocytic leukemia \[[@b72-sensors-08-01366]\]. We refer readers to references \[[@b73-sensors-08-01366]-[@b75-sensors-08-01366]\], since they are comprehensive reviews dealing with DNA-based biosensors.

The simplest strategy to detect nucleic acid hybridisation relies on monitoring the direct oxidation/reduction of nucleotide bases. For example, the purine base guanine (G), can be oxidised at a particular potential, firstly rendering 7,8-dihydro-8-oxoG (commonly referred to as 8-oxoG), which suffers further oxidation reactions \[[@b76-sensors-08-01366]-[@b78-sensors-08-01366]\] ([Figure 6A](#f6-sensors-08-01366){ref-type="fig"}). In principle, the number of G residues present in the ss- nucleic acid probe will lead to a directly proportional reduction or oxidation signal. The most important drawback that presents this simple method to determine hybridisation is the high background current in the absence of the hybridisation event \[[@b75-sensors-08-01366]\]. It should be considered that the G electrochemical signal diminishes upon base pairing; this has been ascribed to the molecule rigidity gained after hybridisation \[79, and references therein\], or to steric hindrance that prevents accessibility of the oxidation sites \[[@b80-sensors-08-01366]\]. To overcome this inconvenience, the replace of G base by inosine, an hypoxantine-derivative nucleoside, proved to be useful \[[@b56-sensors-08-01366],[@b64-sensors-08-01366]\], since its preferential base partner is the same as for G \[[@b81-sensors-08-01366]\]. Therefore, there is a signal increase after pairing of DNA complementary strands, making this a suitable platform to detect the event.

The use of cationic metal complexes that can associate to double-stranded (ds-) DNA stronger than to ss-DNA has been also proposed \[[@b53-sensors-08-01366],[@b54-sensors-08-01366]\]. In this case, small complexes can intercalate between DNA grooves possessing a much higher affinity for the DNA hybridised compared to ss-DNA. The central metal ion can be electrochemically transformed when is close to the electrode surface, and therefore the signal increases as long as hybridisation takes place. A widely used DNA-intercalating metallic complex is Co(2,2′-bipyridy1)~3~^3+^. This compound was used to detect the three-base deletion of ΔF508 DNA sequence, an indicator useful to diagnose cystic fibrosis \[[@b54-sensors-08-01366]\], and the presence of pathogenic *Escherischia coli* bacteria \[[@b53-sensors-08-01366]\]. Another similar compound, Co(1,10-phenanthroline)~3~^3+^, was also used to detect DNA sequence of *Mycobacterium tuberculosis* \[[@b82-sensors-08-01366]\], *Cryptosporidium parvum* \[[@b83-sensors-08-01366]\], hepatitis B virus \[[@b84-sensors-08-01366]\], and the human immunodeficiency virus \[[@b82-sensors-08-01366],[@b85-sensors-08-01366]\]. A variety of other intercalating compounds, such as methylen blue \[[@b86-sensors-08-01366]\], daunomycin and aromatic amines \[[@b87-sensors-08-01366]\], have been used to evidence DNA hybridisation. The two latter ones have been applied to detect the gene encoding for apolipoprotein E, a protein involved in familial dysbetalipoproteinemia \[[@b87-sensors-08-01366]\]. Still another strategy taking advantage of labelled-complementary base sequences has proved to be effective to monitor DNA hybridisation. Labels include electroactive molecules such as ferrocene derivatives \[[@b88-sensors-08-01366]\] ([Figure 6B](#f6-sensors-08-01366){ref-type="fig"}) or enzymes ([Figure 6C](#f6-sensors-08-01366){ref-type="fig"}) \[[@b89-sensors-08-01366]-[@b91-sensors-08-01366]\], as well as other redox-derivative compounds \[[@b92-sensors-08-01366]-[@b95-sensors-08-01366]\].

A variety of arrays have been reported to rise above the limitations and disadvantages occurring when using DNA-based biosensors, and some of them will be detailed in the following item. For a deeper insight on the subject, we refer the readers to exhaustive reviews, as those referenced next \[[@b75-sensors-08-01366],[@b96-sensors-08-01366]-[@b98-sensors-08-01366]\].

2.2.. Avoiding interfering reactions
------------------------------------

Though there are many enzymes whose products can be monitored by amperometry, sometimes complications crop up using the simple model described in point *2.1.1*, since other compounds present in the sample matrix may also be transformed on the electrode set at the chosen potential. The same holds true when directly detecting nucleic acid hybridisation via oxidation of G. Certainly, together with the species indicator of the biochemical event taking place at the biorecognition layer, interferences may also be electrochemically oxidised/reduced. For example, when using an amperometric glucose biosensor, which oxidises the hydrogen peroxide produced by the enzymatic reaction shown in [Fig. 3](#f3-sensors-08-01366){ref-type="fig"}, other endogenous substances, *e.g.* uric and ascorbic acid, gluthatione, cysteine, or exogenous compounds such as manitol, acetaminophene, thiocyanate etc., are also oxidised at the electrode potential \[[@b99-sensors-08-01366]-[@b103-sensors-08-01366]\]. In these cases, different strategies have contributed to solving the problem, namely: (*i*) preventing the interfering compound from occurring in a significant amount nearby the electrode and (*ii*) working at potentials at which oxidation/reduction of interferences is negligible.

The simplest proposal to diminish occurrence of non-desired reactions at the electrode is simply by diluting the sample so that the interferences potentially present in the sample are not readily detected. However, this approach is only useful when dealing with highly sensitive devices, such as the one reported to detect uric acid using uricase \[[@b104-sensors-08-01366]\].

Another straightforward method to prevent interferences from reaching the electrode is by using a selectively-permeable membrane, which can operate based on either charge or size properties. One example of the charge rejection approach has been proposed by Zhang *et al*. \[[@b105-sensors-08-01366]\]. They designed a blood glucose biosensor that uses a Nafion™ membrane to exclude interfering anions. Examples of interference-excluding membranes based upon size used for glucose amperometric biosensors include the dialysis type ones \[[@b100-sensors-08-01366],[@b106-sensors-08-01366]\], polymers, such as overoxidized polypyrrol \[[@b107-sensors-08-01366]\], polydimethylsiloxane \[[@b108-sensors-08-01366]\], poly(1,2-diaminobenzene) \[[@b109-sensors-08-01366]\], poly(1,3-diaminobenzene/resorcinol) \[[@b110-sensors-08-01366],[@b111-sensors-08-01366]\], poly(o-phenylenediamine) \[[@b112-sensors-08-01366]\] and cellulose acetate \[[@b113-sensors-08-01366],[@b114-sensors-08-01366]\]. In all these cases, polymers allow for permeation of molecules having similar molecular weigh to the analyte, interferences of size larger than the analyte being excluded.

Still another way to remove non-desirable species previously to the detection step is by capturing the analyte, and changing the medium where the electrochemical reaction will take place \[[@b59-sensors-08-01366],[@b60-sensors-08-01366],[@b62-sensors-08-01366],[@b115-sensors-08-01366],[@b116-sensors-08-01366]\]. For example, Adam *et al.* have determined the presence of heavy metals in biological fluids with a biosensor which uses metallothionein, a cystein-rich protein that covalently binds heavy metals via its multiple sulfhydril residues \[[@b116-sensors-08-01366],[@b117-sensors-08-01366]\]. The procedure consists of capturing the heavy metal ions by their interaction with the metallothionein protein, previously adsorbed on a hanging mercury drop electrode. After washing the electrode, a differential pulse voltammetry is performed in a convenient supporting electrolyte to register the corresponding signal \[[@b116-sensors-08-01366],[@b118-sensors-08-01366]\]. Magnetic-bead-based biosensors relay on the same principle based on detection of the analyte subsequent to the separative step \[[@b119-sensors-08-01366]\]. In brief, after pairing the target analyte with the biorecognizing element mounted on the beads, the coupled system is magnetically removed from the original sample matrix and transferred to an appropriate interference-free medium for further detection. A number of biosensors have been proposed to detect analytes of clinical interest using this strategy, the device proposed to detect BRCA1 breast cancer gene being one relevant example \[[@b120-sensors-08-01366]\].

The second tactic to avoid interfering reactions consists of working with systems that use electrode potentials at which interferences are not efficiently oxidized/reduced, which can be achieved by using electrochemical mediators \[[@b121-sensors-08-01366]-[@b125-sensors-08-01366]\]. Electrochemical mediators commonly used are chemicals displaying a higher kinetic constant for the electron transfer process at the electrode than that of the product selected to monitor the enzymatic reaction. Thus, the electro-transformation of the mediator (med) is favoured, as compared with that of the product of the enzymatic reaction. These compounds usually act as enzyme (Ez) co-substrates mediating the charge transport between the biological recognition element and the electrode, therefore rendering a catalytic cycle, as described in [Fig. 7](#f7-sensors-08-01366){ref-type="fig"}.

It is worth pointing out that when such a catalytic cycle occurs, there is a substantial improvement of the methodology sensitivity due to the recycling of the electrochemically active species, which can be repetitively transformed. A variety of electrochemical mediators, either soluble or directly attached on the electrode, have been used. Most of them deal with the enzyme-electrically-wiring obstacle. Simultaneously, they prevent from electrochemical oxidation/reduction of interferences and, sometimes, they still improve sensitivity.

Recently, Alves *et al.* have described a very interesting mediator for a glucose biosensor \[[@b126-sensors-08-01366]\]. In this case, iron complexes derived from tetra-2-pyridyl-1,4-pyrazine have been mixed with hexacyanoferrate species to render a supramolecular structure that contains Fe(II) and Fe(III) species, inside a highly π-character network. This polymer exhibits an excellent conductivity together with catalytic activity for H~2~O~2~ electro-reduction, which is displayed by this Prussian Blue-analogue. Therefore, the polymer enables its coupling to a glucose-oxidase enzyme as a redox charge transfer mediator, working at a relatively low potential \[[@b126-sensors-08-01366]\]. Reasonable good performances were also reported for mediators attached on bioelectrodes surface for glucose determination, which include tetracyanoquinodimethane, tetrathiafulvalene, dimethyl ferrocene \[[@b127-sensors-08-01366],[@b128-sensors-08-01366]\], other ferrocene derivatives \[[@b129-sensors-08-01366],[@b130-sensors-08-01366]\], complexes containing Os-bispyridine or derivatives \[[@b131-sensors-08-01366]-[@b139-sensors-08-01366]\], methyl viologen or derivatives \[[@b133-sensors-08-01366],[@b134-sensors-08-01366]\], toluidine blue O \[[@b135-sensors-08-01366]\], poly(allylamine)ferrocene \[[@b140-sensors-08-01366],[@b141-sensors-08-01366]\], Ospoly(allylamine) derivatives \[[@b142-sensors-08-01366]\] and poly(aniline) derivatives \[[@b143-sensors-08-01366]\], among others. Moreover, the ExacTECH™ biosensor from Abbott-Medisense takes advantage of the strategy, using in this case one ferrocene derivative as mediator to monitor glucose blood level \[[@b144-sensors-08-01366]\]. Proposals of clinically-useful biosensors using soluble mediators to detect infection-marker antibodies \[[@b24-sensors-08-01366],[@b25-sensors-08-01366]\], acetylcholine \[[@b145-sensors-08-01366]\], biological oxygen demand \[[@b146-sensors-08-01366]\], as well as other electrode-attached mediators to determine simple molecule analytes, such as glutathione \[[@b132-sensors-08-01366]\], L-alanine and pyruvate \[[@b10-sensors-08-01366]\], lactate \[[@b147-sensors-08-01366]\], and cholesterol \[[@b129-sensors-08-01366]\] accurately have been also reported. Chaubey *et al.* have published an extensive study on mediators for biosensor applications \[[@b148-sensors-08-01366]\].

Likewise, clever improvements to avoid interference reactions and background currents have been proposed when detecting DNA hybridisation. Some approaches follow the same strategies as for enzymatic biosensors, *i.e.* physical separation of the analyte from interferences, decrease of working potentials, or both alternatives at the same time. In one of the proposed separative strategies, the DNA-capturing probe is attached to magnetic beads and, once hybridisation is accomplished, the particles are magnetically removed from the medium. The analyte determination proceeds by electron-transfer-based electrochemical techniques \[[@b60-sensors-08-01366],[@b120-sensors-08-01366]\].

Once more, considering that the potentials at which the nucleotide bases are electro-transformed are quite extreme, severe interferences from oxidation/reduction of other species present in the sample make necessary additional steps to accurately detect hybridisation \[[@b56-sensors-08-01366],[@b59-sensors-08-01366],[@b79-sensors-08-01366],[@b149-sensors-08-01366]-[@b151-sensors-08-01366]\]. That has prompted the development of alternative approaches, as for example, detection of DNA hybridisation by electrocatalytic oxidation of ribose and primary amine residues of nucleotide bases, using copper surfaces \[[@b80-sensors-08-01366]\]. In this approach ss-DNA signal was lower than that generated by ds-DNA, and allowed to detect nucleic acids in concentration at the picomolar level \[[@b80-sensors-08-01366]\]. Another option to detect hybridisation is to oxidise G via a charge transfer mediator, for example the metallic complex Ru(2,2′-bipyridyl)^3+^, which is easily electro-oxidised at a relatively low potential \[[@b152-sensors-08-01366]\]. This strategy prevents from working at extreme potentials and it has proved success to detect, for example, a sequence of BRCA1 breast cancer gene \[[@b153-sensors-08-01366]\].

Strategies used in biosensor technology to prevent interference reactions from species accompanying the analyte are detailed in reviews \[[@b63-sensors-08-01366],[@b74-sensors-08-01366],[@b75-sensors-08-01366],[@b96-sensors-08-01366]\].

2.3.. Preserving the bioreceptor layer
--------------------------------------

Bioreceptors must maintain appropriate biorecognition activity to be used in a biosensing device. Therefore, their structural/conformational integrity must be conserved so as to display a reasonable lifespan. It is obvious that, depending on the complexity of the biorecognition element, the requirements to maintain its integrity will change. In principle, any biological molecule or biomimic assembly capable of recognizing the analyte can be used as a bioreceptor. [Table 1](#t1-sensors-08-01366){ref-type="table"} summarizes the main needs to be taken into account according to the biorecognition element used in the bioreceptor layer.

From Clark\'s first biosensor design, in which a dialysis membrane kept the bioreceptor, glucose oxidase, in a solution which preserved its integrity, changes were brought up attempting to improve the stability of the immobilized biorecognition element, and hence the lifetime of the biosensor.

Numerous biosensors in which the recognizing elements are entrapped in passive matrices such as inert polymers, or where the analyte-capturing molecule is cross-linked with other spectator proteins, have been described \[[@b154-sensors-08-01366],[@b155-sensors-08-01366]\]. In this line, it has been reported the development of diagnostic biosensors retaining the bioactive molecules via crosslinking with carbodiimide or glutaraldehyde to detect, for example, prostate specific antigen \[[@b14-sensors-08-01366]\], *Schistosoma japonicum* antibody \[[@b27-sensors-08-01366]\], specific chagasic antibodies \[[@b25-sensors-08-01366]\], transferrin \[[@b156-sensors-08-01366]\], and creatinine \[[@b157-sensors-08-01366]\], among others.

Various different bioreceptor-capturing, entrapping polymers used to develop clinically suitable biosensors have been described. Among them, conducting polymers have demonstrated several advantages, such as *(i)* to give a support to the biologically-active molecule by chemical interactions, either electrostatic, covalent or non-specific interactions, *(ii)* to allow charge propagation and to "wire" the label (*e.g.* one redox-enzyme) to the electrode, *(iii)* to admit the incorporation of redox mediators, and *(iv)* to enhance mechanical resistance, turning devices more robust. Among these polymers, the pyrrol-based ones have been thoroughly characterised \[[@b158-sensors-08-01366]-[@b161-sensors-08-01366]\]. They display excellent properties to be used for biosensor development, since they render appropriate stability and good conductivity \[[@b162-sensors-08-01366]\]. Polypyrrole-based polymers have been successfully used in biosensors to detect urea by means of ureasa entrapped in it \[[@b163-sensors-08-01366]\], and in those where glucose oxidase is immobilised in a polypyrrole hybrid film, displaying very good performances \[[@b126-sensors-08-01366],[@b164-sensors-08-01366],[@b165-sensors-08-01366]\]. Other conducting polymers have been used. For example, polyaniline was used to detect antibodies \[[@b166-sensors-08-01366]\], and poly(allylamine) derivatives incorporating a charge transfer mediator have also proved to be efficient for enzyme-based amperometric biosensors \[[@b59-sensors-08-01366],[@b136-sensors-08-01366],[@b167-sensors-08-01366]\]. In the last decades, natural polymers, such as chitosan derivatives, have been proposed to immobilize biologically-active species because of their advantageous features such as inertness, biocompatibility, good mechanical resistance, and appropriate film-forming properties \[[@b168-sensors-08-01366]\]. For instance, a biosensor to determine the tumour marker, α-1-feto-protein, whose biorecognition element is an enzyme-labelled antibody, takes advantage of this polymer and a reasonable stability has been reported \[[@b169-sensors-08-01366]\]. A number of other biosensors for clinical applications using modified surfaces with chitosan polymer have been proposed, for example, to detect *Schistosoma japonicum* antigen \[[@b26-sensors-08-01366]\], dengue virus oligonucleotide sequences \[[@b170-sensors-08-01366]\], and to determine choline; in this latter case the enzyme cholinesterase was cross-linked with glutaraldehyde in a chitosan gel \[[@b171-sensors-08-01366]\]. Reviews focusing on polymers used to assemble amperometric biosensors are referenced in \[[@b172-sensors-08-01366]-[@b174-sensors-08-01366]\].

3.. Sensitivity
===============

One of the most relevant tasks when designing a ready-to-use biosensor is to achieve the needed sensitivity. In all cases, the aimed limit of detection, dynamic range, and sensitivity will depend on the natural sample where the device is to be used. Therefore, the expected range of analyte concentration and the interfering substances potentially present in the sample will largely influence the requirements.

Enhancing any analytical method sensitivity means increasing the signal-to-noise ratio. Two obvious lines of attack are possible: augmenting the signal or diminishing the noise. In electron transfer-based biosensor technology, an enhancement of the signal-to-noise ratio is achieved by increasing the number of electroactive detectable analyte-related species and/or by lowering the interferences that reach the electrode thus giving rise to background current noise. The main strategies used to diminish the background currents produced by interferences have already been addressed in point *2.2*. Hence, the "lowering the noise" subject will not be further detailed; we will therefore converge on the topic of signal boosting, which has been faced in the manners described below.

3.1.. Magnifying the electron-transfer process
----------------------------------------------

Different ways of achieving the goal of increasing the number of detectable species are possible, two of which are based on magnifying the electron-transfer process, namely: (i)Recycling the electrochemically-transformed compound. This has already been described above in item *2.2* when considering catalytic enzymatic cycles involving the regeneration of the active-site of the redox enzyme using a charge transfer mediator that is then electro-transformed at the electrode surface (see [Fig. 7](#f7-sensors-08-01366){ref-type="fig"}). Usually, in these cases, the enzyme substrate should be present at excess concentration to keep the enzymatic cycle. The signal that evidences the occurrence of the enzymatic cycle is generally related to the presence (or absence) of the analyte in the sample when performing an indirect (or competitive) immunoassay with electrochemical detection, as described previously in point *2.1.2.*(ii)Amplifying the electron exchange process at the electrode surface using coupled enzymatic systems. In this approach, the analyte (or one analyte-related species), is the substrate of the first enzyme (Ez-1). The analyte and the Ez-1 co-substrate, which is the electro-active species, react with Ez1 to render the products, one of which is the Ez-2 substrate ([Fig. 8](#f8-sensors-08-01366){ref-type="fig"}). Ez-2 reacts with its substrate to regenerate the analyte (or the analyte-related species), thus enabling its recycling to keep consuming Ez-1 co-substrate, this latter one being electrochemically detected. Therefore, even tiny amounts of the analyte can be detected because the consumption of the electroactive species is supported by the cyclic reaction of both enzymes.

Several examples taking advantage of such bi-enzymatic amplification have been described to detect chatecolamines \[[@b175-sensors-08-01366],[@b176-sensors-08-01366]\], IgG and cocaine \[[@b176-sensors-08-01366]\], among others. This approach was also used to detect successfully lactate via coupling the enzymes lactate oxidase and lactate dehydrogenase, immobilised onto aminopropyl controlled-pore glass \[[@b177-sensors-08-01366]\], or a polyaniline film \[[@b178-sensors-08-01366]\]. The basis of these clinically-relevant biosensors is that one of the products of the first enzymatic reaction is the substrate of the second enzyme, which transforms this product back to the initial species. This cyclical conversion allows one electrochemically-active species, acting as co-substrate of the first enzyme, to keep on being consumed, thus multiplying the measured signal.

1.  Producing additional equivalents of electroactive species, generated by a second enzyme that uses a "side product" of the first enzymatic reaction, which had rendered the first equivalent of electroactive species. An amperometric biosensor using this model was presented by Conrath *et al.* to detect inorganic phosphate \[[@b179-sensors-08-01366]\]. In the clinical practice, phosphate levels in both blood and urine are determined as indicative of osteopathies, and of parathyroid function \[[@b180-sensors-08-01366]\]. In Conrath\'s proposal, the first enzyme, maltose phosphorylase, catalyses the reaction between the analyte and maltose, to render β-D-glucose-1-phosphate and α-D-glucose (4). This latter species is further transformed by mutarotase into to β-D-glucose (5). β-D-glucose acts as substrate of glucose oxidase to render glucuronic acid and hydrogen peroxide (6), which is the electrochemically detected species. Another enzyme, acid phosphatase, hydrolyses the "side product", glucose-1-phosphate, generating an extra β-D-glucose (7), which will be also further oxidised according to (6), thus releasing the analyte, phosphate, which can be recycled again.
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In this interesting example, the signal is not only amplified by the extra amount of substrate rendered by the acid phosphatase using a "side product", but also by recycling the analyte \[[@b179-sensors-08-01366]\].

3.2.. Increasing the number of biorecognition species
-----------------------------------------------------

The obvious tactic to raise the amount of the electrochemically-detectable species is enlarging the number of biologically-active molecules in the biorecognition layer, so as to make the analyte-capturing step more efficient. Self-assembled monolayers have proved to be useful in biosensor design but, many times, these structures do not offer the desired signal-to-noise ratio and, therefore, it has been proposed to use multilayer systems. Caruso *et al.* have demonstrated that the signal can be increased using devices with stratified-analogue structure where polymer layers are alternated with layers of the antibody, the analyte being the complementary antigen \[[@b181-sensors-08-01366],[@b182-sensors-08-01366]\]. In a similar way, it has been shown signal enhancement when building up a layer-by-layer, organized supramolecular structure, comprised of a redox polymer and an enzyme-labelled antibody \[[@b137-sensors-08-01366],[@b167-sensors-08-01366],[@b183-sensors-08-01366]\]. In both cases, the basic principle is that the electrochemical response obtained is proportional to the amount of the analyte-related species captured.

Sometimes, a more precise control over surface density of biomolecules to prevent molecular aggregation, or to conduct their attachment in a favourable orientation, leads to improved biosensor performances. Calixarene derivatives have been proposed as linking structures to conduct effective protein immobilization \[[@b184-sensors-08-01366]\]. In one proposal, the calixarene structure has thiol residues which link to the gold surface and, at the opposite side, a crownether structure remains exposed to further link the analyte-capturing biomolecule \[[@b185-sensors-08-01366]\]. Thus, enhanced protein binding was achieved by modifying gold electrodes with calixarene-derived monolayers.

Proper oriented attachment is crucial when the bioreactive species comprises a specific IgG antibody. IgG is a Y-shaped molecule, whose specific antigen-binding sites are located at the end of the "arms", the so-called Fab region; the remaining extremity of the molecule, *i.e.* its base, is named Fc region. When self-assembling IgG-based immunoelectrodes, IgG molecules attach randomly to the surface, and only a fraction of them are useful to capture the analyte. In these cases, it is desired that the IgG Fab region is favourably oriented so as to prevent blockage of the binding sites to effectively capture the antigen. Early studies dealing with this issue were performed by Caruso *et al.* \[[@b186-sensors-08-01366]\]. They demonstrated that electrodes whose surface had been modified with protein A, a molecule that displays high affinity for the Fc region of IgG, increased the further-immobilized IgG molecule, correctly oriented to react with its target analyte \[[@b186-sensors-08-01366]\]. Using the oriented-linking principle to attach the bioreactive molecules, it has been possible to build an electron-transfer based biosensor to detect Staphilococcal enterotoxin B \[[@b187-sensors-08-01366]\]. Moreover, recent studies on biosensors to determine thrombin have demonstrated the critical importance on the immobilization step. The work demonstrates that the efficiency to capture the analyte was enhanced when using streptavidin-biotine interactions to favourably orient the bioreceptor attachment \[[@b48-sensors-08-01366]\]. In line with this, our group has reported preliminary results on one biosensor to detect specific chagasic antibodies whose capturing antigen is a genetically modified protein tailored to react oriented with a carbodiimide-activated surface. The device has shown sensitivity enhancement as compared with biosensors assembled with the same antigen recognition sites, but without the selective, oriented attachment onto the activated surface \[[@b31-sensors-08-01366]\]. Additionally, we could enhance not only the sensitivity but also the selectivity of the method as mentioned above in item *2.1.2*.

Recently, nanotechnology has emerged as the "star" to achieve the signal-augmentation task. Indeed, the last decade has witnessed the blooming of biosensor technology involving nanomatter \[[@b188-sensors-08-01366]-[@b191-sensors-08-01366]\]. The problem is once more tackled by boosting the number of available active sites to interact with the analyte.

Nanomatter is composed of unique functional materials that display incomparable characteristics related with their shape, structure and size (in the order of 1 to 100 nm scale) \[[@b192-sensors-08-01366]\]. According to their shape, nanomaterials have been classified into nanowires, nanotubes, nanobelts, nanosprings, nanorods and nanoparticles. In connection with biosensors, among the most outstanding features of nanomaterials are their mechanical strength, their efficient and tuneable electron-transport properties, and their high surface area per volume unit \[[@b188-sensors-08-01366]\]. Directly related with their arrangement, electron-transfer process may be largely influenced by charge diminution or accumulation when taking place in a linear, one-dimension (1-D) structure, as for example, in a nanowire. This does not occur in a 2-D structure, such as a virtually planar film. When charge transport occurs in a 2-D structure, electrons can be transferred along different conducting roads, even those that circumvent high or low charge density sites. On the other hand, charge transport in nanowires or nanotubes takes place along the line direction, which is the only path available to transfer electrons. This makes these materials competent to give a response upon perturbations from even a few molecules interacting along the line \[[@b188-sensors-08-01366],[@b193-sensors-08-01366]\]. Together with this exceptional susceptibility, and in relation to their high surface-to-volume ratio, nanomaterials offer massive number of sites that can be chemically functionalized. When building electrochemical biosensors, this is translated into a plethora of analyte-interacting sites, thus leading to sensitivity enhancement \[[@b188-sensors-08-01366]-[@b190-sensors-08-01366]\].

Depending on the nanostructure composition, several strategies have been proposed to modify the nanomaterial surface, generally proceeding according to the methods already established to develop amperometric biosensors. For example, gold nanoparticles were utilized to develop amperometric biosensors to determine IgG \[[@b194-sensors-08-01366]\], hepatitis B surface antigen \[[@b195-sensors-08-01366]\], and lactate \[[@b196-sensors-08-01366]\], among others. Also gold nanotubes have been modified by alkylthiols to which the enzymes of interest had been attached, thus allowing to determine clinically-relevant analytes \[[@b197-sensors-08-01366],[@b198-sensors-08-01366]\]. The enzymes glucose-oxidase and horseradish-peroxidase, commonly used in clinical biosensor technology, have been covalently linked via activation using carbodiimide, or cross-linking it with glutaraldehide \[[@b197-sensors-08-01366],[@b198-sensors-08-01366]\]. The same principle described above when addressing DNA-biosensor technology, in which metallic electrochemical mediators are used to catalyse G oxidation, has been also used together with functionalized carbon nanotubes (CNT) to detect the hybridisation event. In this case, the detection limit has been lowered to a few attomoles of the analyte \[[@b199-sensors-08-01366]\]. In another example, the already known discriminative properties of Nafion were combined with the recently-demonstrated hydrogen peroxide catalytic properties of CNT \[[@b200-sensors-08-01366]\]. Thus, Wang *et al.* have reported that it is feasible to suspend CNT in Nafion solutions, the resulting system showing a dramatic decrease of the overpotential for hydrogen peroxide detection; this provides an improved way towards glucose-oxidase biosensors development \[[@b200-sensors-08-01366]\]. It was also demonstrated the feasibility of designing biosensors useful for clinical chemistry analysis by means of CNT-based pastes biocomposite bioelectrodes \[[@b201-sensors-08-01366]\].

The vast number of recently published work involving nanotechnology to design electrochemically-based biosensors demonstrates that this is one of the most fertile fields of research, and that prospects of biosensors useful for clinical diagnosis will be closely related to it. Thorough reviews on this subject are referenced as \[[@b188-sensors-08-01366]-[@b190-sensors-08-01366],[@b193-sensors-08-01366],[@b202-sensors-08-01366]\].

4.. Simplicity of use and packaging
===================================

Protocols to be followed when using biosensors should be as simple as possible, so that the device operation results amenable. This is an important feature to bear in mind, since it is usually related to market acceptability.

Generally, the use of classical amperometric-based biosensors requires a number of consecutive steps. Clever solutions to shorten procedures have been reported, for example, by performing separation-free immunoassays \[[@b203-sensors-08-01366]\]. These amperometric biosensors relay on a self-assembled antibody monolayer attached onto a double-sided microporus gold electrode. The layout allows spatial separation between the excess of conjugate in solution and the conjugate bound to the bioreceptor layer. Therefore, the proposal has advantages with respect to common ELISA, such as fewer steps and the possibility of performing it in the field \[[@b204-sensors-08-01366]-[@b206-sensors-08-01366]\].

Label-free biosensors have also become attractive because of their easiness of use. An outstanding approach has been proposed to determine glucose using glucose-oxidase directly "plugged" to the electrode taking advantage of the controlled electron transference through a CNT \[[@b207-sensors-08-01366]\]. The electrode surface was thiolated, and CNTs were covalently aligned using carbodiimide. The enzyme co-factor was also covalently attached at the opposite end of the nanotubes by using carbodiimide. Finally, the apoenzyme was added, the enzyme was effectively reconstituted and glucose transformation into glucuronic acid was then monitored by amperometry, without using any charge transfer mediator \[[@b207-sensors-08-01366]\]. The reader is referred to a recent review on contacting redox proteins using nanotechnology \[[@b208-sensors-08-01366]\]. In another example, hCG was detected using an immunosensor where Abs against this pregnancy-indicator hormone had been oriented attached by means of protein A. hCG concentration was determined measuring the peak current by square wave stripping voltammetry \[[@b209-sensors-08-01366]\]. Additional applications where label-free biosensors were used can be found in the following references \[[@b210-sensors-08-01366]-[@b214-sensors-08-01366]\]. Some of them also present renewable devices, another attractive characteristic aimed to lower the cost of the analysis \[[@b212-sensors-08-01366]\].

In addition, the need to move classical analytical tools into miniaturised devices is easily understood, since the latter ones reduce production and operative costs, apart from attenuating environmental impact. Certainly, the possibility of working in the micro-scale allows to use few microliters of reagents, thus making the operation not only cheaper than when using macro/semimicro scale techniques but also less hazardous \[[@b215-sensors-08-01366]\]. The development of clinically-useful biosensors is moving in that direction due to the fact that the reactant requirements are definitely lower than those of classical methodologies. Micro-scale biosensor devices intrinsically have the ability to react with the analyte and generate a measurable response within the same compact body. A good example is the enzymatic biosensor to detect lactate in saliva in a one-step analysis \[[@b216-sensors-08-01366]\]. The system consists of a silicon wafer where a three-electrode cell is built up. Lactate oxidase is entrapped in an agarose gel placed inside a cavity of the silicon chip. The sample diffuses through the pores, and the product of the enzymatic reaction is detected by amperometry \[[@b216-sensors-08-01366]\].

5.. Future directions
=====================

Even though it is desirable to perform the clinical-chemistry analysis in only one step, sometimes the complexity of the sample carrying the analyte and/or its low concentration make us to face with challenging problems. The progress in microfluidic systems allows for integration of different steps to perform the analysis within a single package \[[@b217-sensors-08-01366]-[@b219-sensors-08-01366]\]. The steps may include pretreatments, such as filtration, pre-concentration, extraction, derivatization, reaction and, eventually, analyte detection \[[@b220-sensors-08-01366]\]. The so-called lab-on-a-chip technology has emerged as a gifted tool to cope with these real complex samples \[[@b217-sensors-08-01366],[@b221-sensors-08-01366]\]. At the present time, schemes of biosensors coupled to layouts allowing for separative or pre-concentration steps are promising tools to deal with complex-matrix samples \[[@b217-sensors-08-01366]\]. A novel approach has been reported to detect nucleic acids, which illustrates the matter \[[@b222-sensors-08-01366]\]. The device consists of an ultramicroelectrode array where a glass chip is integrated with poly(dimethylsiloxane) channels. An electroactive compound is carried inside liposomes labeled with one ss-DNA tag. Another additional ss-DNA probe is linked to superparamagnetic beads, the target ss-DNA being complimentary to both tags. A magnet captures the liposome-analyte-magnetic bead sandwich inside the microfluidic channel, where the electroactive compound is released to be further electrochemically detected \[[@b222-sensors-08-01366]\]. This appliance is a good example of compact ultra-micro systems that combine microfluidics and amperometric based biosensors.

Considering that samples for clinical analysis are largely complex, the above-mentioned appliances are foreseen as the next-generation diagnostic devices \[[@b23-sensors-08-01366]\]. Furthermore, these devices can help even when the problem magnifies because not only the sample but also the disease is complex, which is the case of cancer. This illness may be shuttled by a variety of genetic or/and epigentic changes directly acting on the overgrowth capacity of the cells. Up to these days, there is not a unique, specific tumor marker that could be used as indicator of every existing type of cancer. Numerous alterations on oncogenes or tumor-suppresor genes may be associated with cancer development, in such a way that using a single DNA-genosensor may not allow to diagnose the illness. Indeed, apart from DNA changes related to cancer, many other alterations occur during the disease. For example, multiple variations evidenced as over/under expression of certain proteins or mRNA, lead to an enormous number of different biomarkers that can be associated with the more than 200 types of cancer \[[@b223-sensors-08-01366],[@b224-sensors-08-01366]\]. In such a complex scenario, new tools are necessary to perform simultaneous measurements of various analytes that generate multiple signals at the same time. Biosensors for clinical-chemistry analysis have demonstrated to move towards simplifying the analytical procedures with the advantage of multiplexing capability \[[@b23-sensors-08-01366]\]. It is worth mentioning that this possibility can provide the physician important information that will facilitate early cancer detection. This is a critical point for treating the disease at an early stage, a fact that leads to improved prognosis \[[@b23-sensors-08-01366],[@b224-sensors-08-01366]\]. Additionally, it is also important to monitor the anti-tumoral drug concentration in the patient\'s fluids as a means to adjust the doses necessary to keep effectiveness of the treatment. In connection with this, it has been proposed a biosensor to detect one of the most used chemotherapy medication, cisplatin \[[@b225-sensors-08-01366]\], using the same strategy already mentioned to determine heavy metal concentration in human fluids \[[@b116-sensors-08-01366]\]. Petrlova\'s *et al.* work \[[@b225-sensors-08-01366]\], is another example in reference to biosensor technology as a powerful option to get clinically relevant information.

Up to now, most of clinical analysis is carried out in centralised laboratories were high-technology equipment is available, and trained personnel perform the determinations under almost ideal conditions, *i.e.* temperature control, use of standard solutions and calibrators, etc. Nevertheless, the actual trend in clinical practice to monitor the health-state of the patient is directed towards point-of-care screening analysis, and household equipment \[[@b226-sensors-08-01366]-[@b228-sensors-08-01366]\]. Moreover, most underserved population in developing countries do not access to state-of-the-art diagnostic methods \[[@b229-sensors-08-01366]\]. The emergence of technology that changes sophisticated diagnostic tools by low-cost, accurate and portable systems seems to be an urgent need, making possible to reach even rural people who hardly move to Health Centres \[[@b24-sensors-08-01366]\]. Nowadays, the development of such new technology seems reachable. Research on biosensors, biotechnology, nanomaterials and microfluidics forefront technology, interacting synergistically, is expected to greatly help to achieve this goal.
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![Scheme depicting the functional principles of an amperometric biosensor.](sensors-08-01366f1){#f1-sensors-08-01366}

![Typical plots of the signals obtained when using electrochemical biosensors based on the amount of electro-transformed species at the electrode by means of (A) chronoamperometry, and (B) potentiometric stripping analysis.](sensors-08-01366f2){#f2-sensors-08-01366}

![Illustration of Clark\'s enzyme electrode displaying the reactions occurring at the inner solution containing the enzyme and at the electrode surface.2. Selectivity-Specificity](sensors-08-01366f3){#f3-sensors-08-01366}

![Bioreceptors eligible for attachment to the electrode surface.](sensors-08-01366f4){#f4-sensors-08-01366}

![Scheme depicting different immunoassay formats using amperometric detection. (A) Biosensor to detect an antigen using a competitive immunoassay format, with a redox-enzyme-labelled antigen and the natural substrate of the enzyme, Ez. (B) Biosensor to detect a specific antibody using an indirect immunoassay format.](sensors-08-01366f5){#f5-sensors-08-01366}

![DNA-based biosensor arrangements. (A) Direct detection of DNA by electro-oxidation of guanine using an electrode poised at a convenient potential. (B) Electrochemical detection of DNA hybridisation using an electrochemical mediator for the oxidation of guanine species, which bounds to the nucleic acid probe, and is afterwards electro-transformed. The signal reduces as the analyte concentration increases. (C) Electrochemical detection of DNA hybridisation using an oligonucleotide modified with a redox enzyme (Ez). The signal increases upon adding the enzyme substrate, once hybridisation took place.](sensors-08-01366f6){#f6-sensors-08-01366}

![Catalytic cycle taking place when using an enzymatic amperometric bioelectrode and an electrochemical mediator that regenerates the original oxidation state of the enzyme redox site.](sensors-08-01366f7){#f7-sensors-08-01366}

![Schematic representation of a bi-enzymatic amperometric biosensor. The analyte, ( ![](sensors-08-01366i1.jpg)) is recycled as long the electroactive species ( ![](sensors-08-01366i2.jpg)) is consumed.](sensors-08-01366f8){#f8-sensors-08-01366}

###### 

Most important requirements to preserve the bioreceptor functionality

  Biorecognition layer (complexity order increases to the bottom)   Main requests for functional integrity (the needs usually add up to the bottom)   
  ----------------------------------------------------------------- --------------------------------------------------------------------------------- -------------------------
  Single molecule                                                   Aptamer / ion carrier (ionophore)                                                 Appropriate withholding
  Antibody / DNA                                                    pH and saline stability                                                           
  Enzyme / high molecular weigh protein                             Absence of certain poisoning products (e.g. heavy metals)                         
  Membrane receptor                                                 Mechanic protection                                                               
  Organelle (chloroplast, mitochondrion, etc)                       Appropriate osmotic pressure, oxygen                                              
  Cell                                                              Nutrients                                                                         
  Tissue                                                                                                                                              
  Organ                                                             Undamaged tissue                                                                  
